NCT05636228View on ClinicalTrials.gov

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

August 22, 2024

Study Completion Date

August 22, 2024

Conditions
Acute Infectious Keratoconjunctivitis
Interventions
DRUG

INV-102

INV-102 Ophthalmic Solution

DRUG

Vehicle

Vehicle Ophthalmic Solution

Trial Locations (12)

10330

King Chulalongkorn Memorial Hospital, Bangkok

10400

Mahidol university, Bangkok

27529

Oculos Clinical Research, Garner

33140

Quantum Clinical Trials, Miami Beach

33155

D & H National Research Centers, INC, Miami

My Community Research Center, Inc., Miami

33773

Shettle Eye Research, Largo

45701

Athens Eye Care, Athens

66762

Kannarr Eye Center, Pittsburg

78738

Revolution Research/ Lake Travis Eye and Laser Center, Lakeway

91107

Foothill Eye Institute, Pasadena

91204

Global Research Management, Glendale

Sponsors

Lead Sponsor

Invirsa, Inc.
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Invirsa, Inc.

INDUSTRY